Skip to content

Trial on oral iron preparation in iron deficiency anaemia in pregnancy

A randomized controlled trial comparing the efficacy, tolerability and cost of oral iron preparations in iron deficiency anemia in pregnancy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/08/020863
Enrollment
120
Registered
2019-08-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O098- Supervision of other high risk pregnancies

Interventions

Intervention1: ferrous fumarate: Ferrous fumarate (152 mg contains 50 mg elemental iron and 0.75 mg folic acid) to be prescribed 4 times daily Intervention2: ferrous ascorbate: Ferrous ascorbate (100

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Pregnant women with age between 20 and 40 years and period of gestation from 12 to 30 weeks. 2. Hemoglobin ranging from 7 to 10.5 g% at the start of the study 3. Treatment naïve patients 4. Singleton pregnancy 5. Patients willing to give written informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnant women with any other types of anemia such as megaloblastic anemia, thalassemia, sickle cell anemia, anemia of chronic disease, hemolytic anemia and anemia due to chronic blood loss. 2. Pregnant women with Hb 10.5g% 3. Pregnant women with known hypersensitivity to iron preparations 4. Pregnant women with any other comorbidities such as renal or hepatic impairment, cardiovascular diseases, preeclampsia, GDM, thyroid disorders, acid peptic disease, esophagitis and malabsorption syndrome. 5. Treatment with any other investigational drug in the last 1 month before study entry 6. Multiple pregnancy

Design outcomes

Primary

MeasureTime frame
Proportion of participants becoming non-anemic [Hbâ?¥ 11g%] at the end of the studyTimepoint: Proportion of participants becoming non-anemic [Hbâ?¥ 11g%] at the end of the study

Secondary

MeasureTime frame
Change in hemoglobin levels based on the weeks of gestationTimepoint: 8 week;cost of individual drug therapyTimepoint: 8 week;incidence of any adverse eventsTimepoint: 8 week;proportion of participants achieving normal iron indices like serum iron, ferritin, TIBC, transferrin saturationTimepoint: 8 week;proportion of participants achieving normal RBC indices like PCV, MCV, MCH, MCHCTimepoint: 8 week

Countries

India

Contacts

Public ContactDr Nanda Gamad

PGIMER

nanda.gamad@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026